Simvastatin
The active substance of Simcovas is simvastatin. Simcovas is a medicine used to lower the level of total cholesterol, "bad" cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. Additionally, Simcovas increases the level of "good" cholesterol (HDL cholesterol). Simcovas belongs to a group of medicines called statins.
Cholesterol is one of several fatty substances found in the bloodstream. Total cholesterol is mainly made up of LDL and HDL cholesterol.
LDL cholesterol is often referred to as "bad" cholesterol because it can build up in the walls of the arteries, forming plaque. If the plaque builds up, it can lead to narrowing of the arteries. This narrowing can slow down or block the flow of blood to vital organs, such as the heart and brain. Blocking the flow of blood can lead to a heart attack or stroke.
HDL cholesterol is often referred to as "good" cholesterol because it helps prevent the buildup of "bad" cholesterol in the walls of the arteries and protects against heart disease.
Triglycerides are another type of fat in the blood that can increase the risk of heart disease.
While taking this medicine, the patient should remain on a low-cholesterol diet.
Simcovasis used as a supplement to a cholesterol-lowering diet in cases of:
In most patients, there are no direct symptoms of high cholesterol levels. The doctor may assess the cholesterol level by ordering a simple blood test. The patient should regularly attend follow-up visits, monitor their blood cholesterol levels, and discuss their treatment goals with their doctor.
In case of doubt about whether a medicine being taken is listed above, the doctor should be consulted.
Before starting to take Simcovas, the patient should discuss it with their doctor or pharmacist.
The patient should inform their doctor:
The doctor should perform a blood test before starting to take Simcovas and during treatment if the patient has any liver problems.
The test checks the liver function.
After starting treatment with Simcovas, the doctor may also consider it necessary to perform blood tests to check liver function.
During treatment with this medicine, the doctor will closely monitor the patient for symptoms of diabetes or the risk of developing diabetes. Patients at risk of developing diabetes are those with high blood sugar and fat levels, overweight, and high blood pressure.
The risk of muscle tissue breakdown is higher in patients taking Simcovas in higher doses, especially at a dose of 80 mg. The risk of muscle tissue breakdown is also higher in certain groups of people. The patient should consult their doctor if:
The doctor or pharmacist should also be informed if muscle weakness persists. To diagnose and treat this condition, additional tests and medications may be necessary.
The safety and efficacy of Simcovas have been studied in boys aged 10-17 years and girls who have been menstruating for at least one year (see section 3: "How to take Simcovas").
No studies have been conducted on the use of Simcovas in children under the age of 10. For more detailed information, the patient should consult their doctor.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take, including those that contain any of the following active substances:
Grapefruit juice contains one or more ingredients that affect the action of some medicines in the body, including Simcovas. Grapefruit juice should be avoided.
Simcovas should not be taken if the patient is pregnant, trying to become pregnant, or suspects they may be pregnant. If the patient becomes pregnant while taking Simcovas, they should stop taking the medicine immediately and consult their doctor.
Simcovas should not be taken during breastfeeding, as it is not known whether the medicine is excreted in breast milk.
Before taking any medicine, the patient should consult their doctor or pharmacist.
It is unlikely that Simcovas will affect the ability to drive or use machines. However, it should be taken into account that some people may experience dizziness after taking Simcovas.
If the patient has been diagnosed with intolerance to some sugars, they should contact their doctor before taking the medicine.
The doctor will determine the appropriate dose of Simcovas for the patient, depending on their condition, treatment, and individual risk assessment.
This medicine should always be taken according to the doctor's or pharmacist's instructions. In case of doubts, the doctor or pharmacist should be consulted.
While taking Simcovas, the patient should follow a low-cholesterol diet.
Dosage:
The recommended dose is 5 mg, 10 mg, 20 mg, 40 mg, or 80 mg of simvastatin, taken orally, once a day.
Adults:
The usual starting dose is 10 mg, 20 mg, or in some cases 40 mg per day.
The doctor may adjust the dosage after at least 4 weeks, up to a maximum dose of 80 mg once a day. The patient should not take more than 80 mg per day.
The doctor may prescribe lower doses, especially if the patient is taking any of the medicines listed above or has certain kidney diseases.
A dose of 80 mg is recommended only for adult patients with very high blood cholesterol levels and a high risk of developing heart disease, who have not reached their target cholesterol level with a lower dose.
The usual starting dose for children (aged 10-17 years) is 10 mg per day in the evening.
The maximum recommended dose is 40 mg per day.
Method of administration:
Simcovas should be taken in the evening. The medicine can be taken with or without food. Simcovas should be taken continuously until the doctor decides to stop it.
If the doctor has prescribed Simcovas with another cholesterol-lowering medicine that contains a bile acid sequestrant, Simcovas should be taken at least 2 hours before or 4 hours after taking the bile acid sequestrant.
If the patient has any questions about using this product, they should consult their doctor or pharmacist.
Like all medicines, Simcovas can cause side effects, although not everybody gets them.
The following terms are used to describe how often side effects are reported:
The following serious side effects have been reported rarely.
The following serious side effect has been reported very rarely:
The following side effects have also been reported, but their frequency cannot be estimated from the available data (frequency not known):
The following possible side effects have been observed with some statins:
Laboratory test results
Elevated muscle enzyme activity (creatine kinase) in the blood and abnormal liver function test results have been observed.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be gathered on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The medicine should not be taken after the expiry date stated on the carton after EXP. The expiry date refers to the last day of the month stated.
The medicine should not be stored at temperatures above 30°C.
The medicine should be stored in its original packaging to protect it from light and moisture.
HDPE containers: after opening, store at a temperature below 25°C and use within 6 months.
Medicines should not be disposed of via wastewater or household waste. The pharmacist should be asked how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance is simvastatin. Each film-coated tablet contains 20 mg or 40 mg of simvastatin.
The other ingredients of the medicine are:
Tablet core:lactose monohydrate, microcrystalline cellulose, maize starch, butylhydroxyanisole (E 320), ascorbic acid, anhydrous citric acid, colloidal anhydrous silica, talc, magnesium stearate.
Coating:hypromellose (Pharmacoat 606), hypromellose (Methocel E15 LV Premium), red iron oxide (E 172), yellow iron oxide (E 172), triethyl citrate, titanium dioxide (E 171), talc, povidone K-30.
Simcovas, 20 mg, are oval, biconvex, film-coated tablets, beige in color, with a score line on one side.
The film-coated tablets can be divided into equal doses along the score line.
Simcovas, 40 mg, are oval, biconvex, film-coated tablets, brick-red in color, with a score line on one side.
The film-coated tablets can be divided into equal doses along the score line.
The film-coated tablets are packaged in blisters in a cardboard box or in HDPE containers.
Package sizes:
Blisters:
Simcovas, 20 mg and 40 mg: 28 and 30 film-coated tablets.
HDPE containers:
Simcovas, 20 mg: 250 and 500 film-coated tablets.
Simcovas, 40 mg: 250 film-coated tablets.
Not all pack sizes may be marketed.
Actavis Group PTC ehf.
Dalshraun 1, 220 Hafnarfjörður
Iceland
Balkanpharma-Dupnitsa AD
3, Samokovsko Shosse Str.
2600 Dupnitsa, Bulgaria
Teva Pharmaceuticals Polska Sp. z o.o., ul. Emilii Plater 53, 00-113 Warsaw, tel. (22) 345 93 00.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.